Strategic Outreach Pulmonx specializes in minimally invasive COPD/emphysema treatment with the Zephyr Endobronchial Valve, presenting a sales angle to healthcare systems, hospitals, and payer organizations seeking less invasive lung interventions and potential reductions in post-procedure recovery costs.

Clinical Adoption Target pulmonology and interventional pulmonology programs that perform bronchoscopic procedures; emphasize training and credentialing support since usage is restricted to trained physicians.

KOL Engagement Leverage high-profile conference participation and investor/analyst events to identify regional key opinion leaders and hospital decision-makers for advocacy, case studies, and peer-to-peer education.

Financial Fit Align discussions with hospital procurement teams around potential cost-benefit care pathways, including shorten length of stay, reduction in COPD-related readmissions, and payer coverage implications to facilitate adoption and reimbursement planning.

Expansion Signals Given recent leadership changes and ongoing conference engagements, pursue expansion in mid-to-large health systems, academic centers, and multisite networks where a broader introduction of Zephyr valves could scale quickly with training and support packages.